Approximately 75% of all disease-relevant human proteins, including those involved in
intracellular protein–protein interactions (PPIs), are undruggable with the current drug …

As a versatile therapeutic modality, peptides attract much attention because of their great
binding affinity, low toxicity, and the capability of targeting traditionally “undruggable” protein …

Non-viral vehicles hold therapeutic promise in advancing the delivery of a variety of cargos
in vitro and in vivo, including small molecule drugs, biologics, and especially nucleic acids …

Cyclic cell-penetrating peptides are relatively a newer class of peptides that have a huge
potential for the intracellular delivery of therapeutic agents aimed at treating challenging …

For the longest time, the field of nucleic acid delivery has remained skeptical whether or not
polycationic drug carrier systems would ever make it into clinical practice. Yet, with the …

Nucleic acid therapeutics can be used to control virtually every aspect of cell behavior and
therefore have significant potential to treat genetic disorders, infectious diseases, and …

Novel materials have been developed because of technological advancements combined
with material research. Metal-organic frameworks (MOF) technology has been investigated …

Cell delivery reagents often exploit the endocytic pathway as a route of cell entry. Once
endocytosed, these reagents must overcome endosomal entrapment to ensure the release …

Metal–organic frameworks (MOFs) have recently been demonstrated to be excellent
platforms for biomedical applications. On account of their porous nature and modular …

Ribonucleic acid interference (RNAi) is an innovative treatment strategy for a myriad of
indications. Non-viral synthetic nanoparticles (NPs) have drawn extensive attention as …